An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Cheung, Melissa C ^a,b   Revers, Leigh ^c   Perampalam, Subodini ^c   Wei, Xin ^c   Kiarash, Reza ^c   Green, David E ^d,e   Abdul Wahid, Aws ^c   Gariépy, Jean ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b Sunnybrook Health Sciences Centre   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; RIBOSOME INACTIVATING PROTEIN; SHIGA LIKE TOXIN 1 ISOLEUCYLTYROSYLSERYLASPARTYLLYSYLLEUCYLMETHIONINE; UNCLASSIFIED DRUG; VEROTOXIN 1; CELL SURFACE RECEPTOR; IMMUNOGLOBULIN G; PEPTIDE LIBRARY;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DISSOCIATION CONSTANT; DRUG BINDING; DRUG DISTRIBUTION; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MELANOMA; MELANOMA CELL; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; SCID MOUSE; SURVIVAL RATE; TUMOR REGRESSION; XENOGRAFT; ANIMAL; BIOCATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG SCREENING; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MOUSE MUTANT; PATHOLOGY; PROTEIN BINDING; PROTEIN TRANSPORT; REMISSION; SURVIVAL; TUMOR CELL LINE;

MUS;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; BIOCATALYSIS; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULIN G; MELANOMA; MICE; MICE, SCID; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTORS, CELL SURFACE; REMISSION INDUCTION; RIBOSOME INACTIVATING PROTEINS; SHIGA TOXIN 1; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77649129744     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-28     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96. 10.3322/CA.2007.0010, 18287387.
2. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004, 351(10):998-1012. 10.1056/NEJMra041245, 15342808.
3. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007, 6(5):349-356. 10.1038/nrd2241, 17431406.
4. Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov Today 2008, 13(1-2):30-37. 10.1016/j.drudis.2007.09.003, 18190861.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342. 10.1056/NEJMoa032691, 15175435.
6. Chabner BA, Roberts TG. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 2005, 5(1):65-72. 10.1038/nrc1529, 15630416.
7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792. 10.1056/NEJM200103153441101, 11248153.
8. Frankel AE, Fleming DR, Powell BL, Gartenhaus R. DAB389IL2 (ONTAK) fusion protein therapy of chronic lymphocytic leukaemia. Expert Opin Biol Ther 2003, 3(1):179-186.
9. Pastan I. Immunotoxins containing Pseudomonas exotoxin A: a short history. Cancer Immunol Immunother 2003, 52(5):338-341.
10. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006, 6(7):559-565. 10.1038/nrc1891, 16794638.
11. Thorburn A, Thorburn J, Frankel AE. Induction of apoptosis by tumor cell-targeted toxins. Apoptosis 2004, 9(1):19-25. 10.1023/B:APPT.0000012118.95548.88, 14739595.
12. Holzman DC. Whatever happened to immunotoxins? Research, and hope, are still alive. J Natl Cancer Inst 2009, 101(9):624-625. 10.1093/jnci/djp110, 19401548.
13. Bray MR, Bisland S, Perampalam S, Lim WM, Gariepy J. Probing the surface of eukaryotic cells using combinatorial toxin libraries. Curr Biol 2001, 11(9):697-701. 10.1016/S0960-9822(01)00207-X, 11369233.
14. Sandvig K. Shiga toxins. Toxicon 2001, 39(11):1629-1635. 10.1016/S0041-0101(01)00150-7, 11595626.
15. Caprioli J, Peng L, Remuzzi G. The hemolytic uremic syndromes. Curr Opin Crit Care 2005, 11(5):487-492. 10.1097/01.ccx.0000176688.10810.30, 16175037.
16. Cherla RP, Lee SY, Tesh VL. Shiga toxins and apoptosis. FEMS Microbiol Lett 2003, 228(2):159-166. 10.1016/S0378-1097(03)00761-4, 14638419.
17. Ching JC, Jones NL, Ceponis PJ, Karmali MA, Sherman PM. Escherichia coli shiga-like toxins induce apoptosis and cleavage of poly(ADP-ribose) polymerase via in vitro activation of caspases. Infect Immun 2002, 70(8):4669-4677. 10.1128/IAI.70.8.4669-4677.2002, 128130, 12117981.
18. Narayanan S, Surendranath K, Bora N, Surolia A, Karande AA. Ribosome inactivating proteins and apoptosis. FEBS Lett 2005, 579(6):1324-1331. 10.1016/j.febslet.2005.01.038, 15733836.
19. Stirpe F. Ribosome-inactivating proteins. Toxicon 2004, 44(4):371-383. 10.1016/j.toxicon.2004.05.004, 15302521.
20. Deresiewicz RL, Calderwood SB, Robertus JD, Collier RJ. Mutations affecting the activity of the Shiga-like toxin I A-chain. Biochemistry 1992, 31(12):3272-3280. 10.1021/bi00127a032, 1554712.
21. Onda M, Nagata S, FitzGerald DJ, Beers R, Fisher RJ, Vincent JJ, Lee B, Nakamura M, Hwang J, Kreitman RJ, et al. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 2006, 177(12):8822-8834.
22. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002, 2(10):750-763. 10.1038/nrc903, 12360278.
23. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG, Pehamberger H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998, 4(2):232-234. 10.1038/nm0298-232, 9461199.
24. Reilly RM, Kiarash R, Sandhu J, Lee YW, Cameron RG, Hendler A, Vallis K, Gariepy J. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med 2000, 41(5):903-911.
25. Keppler-Hafkemeyer A, Brinkmann U, Pastan I. Role of caspases in immunotoxin-induced apoptosis of cancer cells. Biochemistry 1998, 37(48):16934-16942. 10.1021/bi980995m, 9836586.
26. Keppler-Hafkemeyer A, Kreitman RJ, Pastan I. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int J Cancer 2000, 87(1):86-94. 10.1002/1097-0215(20000701)87:1<86::AID-IJC13>3.0.CO;2-I, 10861457.
27. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 1988, 171(1-2):45-50. 10.1111/j.1432-1033.1988.tb13756.x, 3276522.
28. Jetzt AE, Cheng JS, Tumer NE, Cohick WS. Ricin A-chain requires c-Jun N-terminal kinase to induce apoptosis in nontransformed epithelial cells. Int J Biochem Cell Biol 2009, 41(12):2503-2510. 10.1016/j.biocel.2009.08.007, 19695342.
29. Binz HK, Amstutz P, Pluckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005, 23(10):1257-1268. 10.1038/nbt1127, 16211069.
30. Larson AR, Konat E, Alani RM. Melanoma biomarkers: current status and vision for the future. Nat Clin Pract Oncol 2009, 6(2):105-117. 10.1038/ncponc1296, 19107110.
31. Dietrich A, Tanczos E, Vanscheidt W, Schopf E, Simon JC. High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur J Cancer 1997, 33(6):926-930. 10.1016/S0959-8049(96)00512-6, 9291817.
32. Goto Y, Ferrone S, Arigami T, Kitago M, Tanemura A, Sunami E, Nguyen SL, Turner RR, Morton DL, Hoon DS. Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res 2008, 14(11):3401-3407. 10.1158/1078-0432.CCR-07-1842, 2686117, 18519770.
33. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 1992, 89(2):466-470. 10.1073/pnas.89.2.466, 48259, 1731316.
34. Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965, 19(6):739-744. 10.1016/0006-291X(65)90320-7, 4953930.
35. Morgan AC, Galloway DR, Reisfeld RA. Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma 1981, 1(1):27-36.
36. Woodman AC, Sugiyama M, Yoshida K, Sugino T, Borgya A, Goodison S, Matsumura Y, Tarin D. Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol 1996, 149(5):1519-1530. 1865276, 8909242.
37. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull 1995, 37(4):417-429. 10.1016/0361-9230(95)00040-2, 7620916.
38. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H, Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991, 65(1):13-24. 10.1016/0092-8674(91)90403-L, 1707342.
39. Thies A, Moll I, Berger J, Wagener C, Brummer J, Schulze HJ, Brunner G, Schumacher U. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 2002, 20(10):2530-2536. 10.1200/JCO.2002.05.033, 12011132.
40. Birch M, Mitchell S, Hart IR. Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res 1991, 51(24):6660-6667.
41. Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, Castello G. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005, 11(5):1835-1841. 10.1158/1078-0432.CCR-04-1887, 15756007.
42. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82(13):1107-1112. 10.1093/jnci/82.13.1107, 2359136.
43. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, Smulson M. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 1999, 274(33):22932-22940. 10.1074/jbc.274.33.22932, 10438458.
44. Garred O, Dubinina E, Polesskaya A, Olsnes S, Kozlov J, Sandvig K. Role of the disulfide bond in Shiga toxin A-chain for toxin entry into cells. J Biol Chem 1997, 272(17):11414-11419. 10.1074/jbc.272.17.11414, 9111051.
45. Fraser ME, Chernaia MM, Kozlov YV, James MN. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 A resolution. Nat Struct Biol 1994, 1(1):59-64. 10.1038/nsb0194-59, 7656009.
46. Deresiewicz RL, Austin PR, Hovde CJ. The role of tyrosine-114 in the enzymatic activity of the Shiga-like toxin I A-chain. Mol Gen Genet 1993, 241(3-4):467-473. 10.1007/BF00284701, 8246901.
47. Hovde CJ, Calderwood SB, Mekalanos JJ, Collier RJ. Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I. Proc Natl Acad Sci USA 1988, 85(8):2568-2572. 10.1073/pnas.85.8.2568, 280038, 3357883.